Thursday, April 7, 2022

Alembic pulls blood pressure generic after complaint reveals labeling mix-up


Generic drugmaker Alembic Pharmaceuticals is recalling one lot of 20 mg telmisartan tablets after a bottle was found to contain the wrong dose. 

The India-based company received a market complaint that a single 30-count bottle with a 20 mg label instead contained 40 mg tablets, according to a notice posted by the FDA.  

Patients who take a double dose of the hypertension med over a prolonged period of time could suffer low blood pressure, worsening kidney function or a potentially life-threatening elevation of potassium levels, Alembic warned. As of Wednesday, the company said it hadn’t received any side effect reports linked to the suspect lot. 

The lot in question expires in March 2022. Alembic didn’t specify how many bottles the recall includes, and wasn’t immediately available to respond to Fierce Pharma’s request for comment. 

RELATED: Dr. Reddy’s pulls hundreds of thousands of bottles of Lipitor generic over impurity fears

Alembic is contacting its distributors and sellers to pursue returns of the affected telmisartan tablets, which were shipped across the U.S. Patients with 20 mg tablets covered by the recall should talk to a healthcare professional for a replacement before stopping use of the drug, Alembic said. 

The recall notice was posted by Alembic’s Bridgewater, New Jersey, operation. The company didn’t say where the telmisartan tablets had been manufactured and bottled, nor where the market complaint was received.

The company, best known for manufacturing anti-infective, analgesic and cough and cold therapies, operates six formulation facilities and three active pharmaceutical ingredients (API) plants in India, according to Alembic’s website. 

RELATED: Sagent pulls 3 lots of phenylephrine after customer finds a loosely sealed vial

Meanwhile, this wasn’t the first labelling mix-up to land a company on the FDA’s recall list this year. Generics maker Meitheal Pharmaceuticals in January yanked one lot of the muscle relaxant cisatracurium besylate over what the Institute for Safe Medication Practices called an “extremely hazardous packaging error.” 

The pull stemmed from a complaint that cartons labeled as cisatracurium contained vials mislabeled as phenylephrine hydrochloride, used to treat low blood pressure, often before surgery. Meitheal at the time said it hadn’t received any side effect reports, but warned that accidental treatment with phenylephrine could raise blood pressure, cause abnormal heart rhythms or reduce blood supply to the heart or brain—all of which could potentially be fatal.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...